PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore
- Written by The Bulletin
.
More Articles ...
- Sunlight REIT secures an additional HK$800 million Sustainability-linked Loan from BOCHK
- Comba Telecom Releases 4G/5G (8TR) Green Integrated Base Station Antenna
- AWS and HKSTP Announce Strategic Collaboration to Accelerate Innovation and Technology Development in Hong Kong
- SUNeVision Welcomes the Court of Appeal's Ruling on Potential Breaches of Lease Conditions of Data Centers in HKSTP Industrial Estates
- Drunk Robots Finds New Partners and Increases the Prize Pool in $METAL
- Meta Health Appoints Dr Bernard Ng as Chairman of the Board and Group CEO
- Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
- WEAVE LIVING and PGIM REAL ESTATE Join Forces for a USD200 Million Urban Living Joint Venture
- AXA launches "AXA Climate School for university students in Hong Kong"
- Hantec Financial will attend Wiki Finance Expo 2022 in Vietnam, HCMC
